📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Bal Pharma Q3 FY26 Consolidated PAT Jumps 245% YoY to ₹1.79 Cr; Revenue Up 20%
Bal Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 19.8% YoY to ₹87.69 crore. The bottom line saw significant expansion, with net profit surging 245% YoY to ₹1.79 crore compared to ₹0.52 crore in the same quarter last year. On a sequential basis, revenue grew by 18.4% and profit more than doubled from ₹0.72 crore in Q2 FY26. The company continues to operate in a single segment, Pharmaceuticals, and maintained an unmodified audit opinion.
Key Highlights
Consolidated Revenue from operations increased by 19.8% YoY to ₹8,768.97 Lakhs.
Net Profit for the quarter surged 245% YoY to ₹179.06 Lakhs from ₹51.79 Lakhs.
Earnings Per Share (EPS) improved significantly to ₹1.12 from ₹0.33 in the year-ago period.
Profit Before Tax (PBT) grew by 216% YoY, reaching ₹179.05 Lakhs.
Nine-month (9M FY26) consolidated net profit stands at ₹271.63 Lakhs compared to ₹181.82 Lakhs YoY.
💼 Action for Investors
The sharp jump in profitability and steady double-digit revenue growth are positive indicators for this small-cap pharma player. Investors should monitor the sustainability of these improved margins in the upcoming quarters.